SCIENTIFIC PROGRAMME

2 December 2021, Thursday COURSES-ONLINE PROGRAMME

HALL 1
08:30 – 09:20

Nursing Care in Gastrointestinal Cancers
Moderator:
TBA

08:30-08:40

  • Symptom Control in Gastrointestinal Tumors - TBA

08:40-08:50

  • Wound and Stoma Care After Gastrointestinal Tumor Surgery - TBA

08:50-09:00

  • Psychosocial Care During the Gastrointestinal Cancers CourseTBA

09:00-09:10

  • Palliative Care in Gastrointestinal Tumors - TBA

09:10-09:20

  • Symptom Management in Gastrointestinal Tumors - TBA
09:20 - 09:30Break
09:30 – 10:30

Rare Gastrointestinal Tumors Course
Chairs:
TBA, TBA

09:30 - 09:45   

  • Gastric Lymhoma - TBA

09:45 – 10:00     

  • Hemangioendotelyoma - TBA

10:00 - 10:15    

  • Small Intestinal Cancer - TBA

10:15 - 10:30    

  • Appendix Mucinous Neoplasia - TBA
10:30 - 10:40Break
10:40 – 12:10

Special Issues in the Management of Gastrointestinal Cancers
Chairs:
TBA, TBA

10:40-10:50

  • Managing Chemotherapy Induced Neutropenia Gastrointestinal Cancers - TBA

10:50-11:05

  • Practical Approach to Drug Allergies in Gastrointestinal Oncology - TBA, TBA

11:05- 11:25

  • Principles of Nutrional Support in Gastrointestinal Cancer Patients - TBA

11:25- 11:40

  • Management of Chemotherapy Associated Hepatotoxicity - TBA

11:40- 11:55

  • How Safe is Immunotherapy, How Can We Recognise and Treat Immune-Related Toxicity - TBA

11:55- 12:10

  • Addressing Cardiac Toxicity in GI Cancer Patient - TBA
12:10 - 12:20Break
12:20 – 13:05

Covid Pandemia and  Gastrointestinal Oncology
Chairs:
TBA, TBA

12:20-12:35

  • Caring GI Cancer Patients During Covid Pandemia - TBA

12:35-12:50

  • Adult Vaccination in Patients with GI Cancers During Covid Era - TBA

12:50-13:05

  • Covid Vaccination in Cancer Patients - TBA
13:05 – 13:30Lunch
13:30 – 15:00

CRC Pathophysiology and  Genetics Course
Chairs: TBA, TBA, TBA, TBA

13:30-13:45

  • Obesity and Colorectal Carcinogenesis - TBA

13:45-14:00

  • NLR and Inflammation Colon Cancer - TBA

14:00-14:15

  • Vitamin D and Colon Cancer - TBA

14:15-14:35

  • Hereditary Basis of Colon Cancer - TBA

14:55-15:00 Discussion: TBA, TBA

15:00 - 15:15Break
15:15 – 16:45

Supportive Care in GI Cancers Course
Chairs: TBA, TBA

15:15-15:30

  • Nause and Vomitting  - TBA

15:30-15:45

  • Pain Management - TBA

15:45-16:00

  • Neutropenia Prophylaxis and Treatment - TBA

16:00-16:15

  • Thrombocytopenia Causes and Management - TBA

16:15-16:30

  • Anticoagulants in Advanced Pancreatic Cancer - TBA

16:30-16:45

  • Principles of Intensive Care in Gastrointestinal Oncology - TBA
16:45 - 17:00Break
17:00 – 19:10

Role Radiology and Nuclear Medicine in the Management of Gastrointestinal Cancer Course
Chairs: TBA, TBA

17:00-17:15

  • Principles of Radiological Imaging in Gastrointestinal Oncology - TBA

17:15-17:35

  • Cross Sectional Imaging of Abdomen - TBA

17:35-17:50

  • Cross Sectional Imaging of Thorax - TBA

17:50-18:10

  • Principles of Radiological Ablative Treatments - TBA

18:10-18:30

  • Principles of Embolization Treatments in GI Cancers - TBA

18:30-18:50

  • Nuclear Imaging in Gastrointestinal Cancers - TBA

18:50-19:10

  • Essentials of Radionuclide Treatment for GI Cancers - TBA
19:10 - 19:30Break
19:30 – 20:30

Tumor Board Multidisiplinary Approach to a Biliary Tract Cancer
Moderator: TBA

19:30-19:45

  • Radiology: TBA

19:45-19:55

  • Pathology: TBA

19:55-20:10

  • Surgery: TBA

20:10-20:30

  • Medical Oncology: TBA
HALL 2
08:30 – 09:50

Epidemiology of Gastrointestinal Cancers Course
Moderators:
TBA, TBA

08:30-08:40

  • Esophageal Cancers: TBA

08:40-08:50

  • Gastric Cancers: TBA

08:50-09:00

  • Small Bowel Cancer: TBA

09:00-09:10

  • Colon Cancer: TBA

09:10-09:20

  • Anal Cancer: TBA

09:20-09:30

  • Pancreatic Cancer: TBA

09:30-09:40

  • Biliary Cancer: TBA

09:40-09:50

  • Hepatocellular Cancer: TBA
09:50 - 10:05Break
10:05 – 11:55

Principles of Surgery in Gastrointestinal Oncology Course
Moderator:
TBA

10:05-10:15

  • Introduction: TBA

10:15-10:25

  • Esophageal Surgery: TBA

10:25-10:35

  • Gastric Surgery: TBA

10:35-10:45

  • Colon Surgery: TBA

10:45-10:55

  • Rectal Surgery: TBA

10:55-11:05

  • Hepatik: TBA

11:05-11:15

  • Biliary Surgery: TBA

11:15-11:25

  • Gall Bladder: TBA

11:25-11:35

  • Pancreatic Surgery: TBA

11:35-11:45

  • NET: TBA

11:45-11:55

  • GIST: TBA
11:55 - 12:30Lunch
12:30 – 13:40

Pathology Course: Outlines of Gastrointestinal and Hepatopancreatobiliary Malignant Tumors
Moderators:
 TBA, TBA

12:30-12:40

  • Pathology of Esophagial Carcinomas - TBA

12:40-12:50

  • Pathology of Gastric Carcinomas - TBA

12:50-13:00

  • Pathology of Colorectal Carcinomas - TBA

13:00-13:10

  • Pathology of Malignant Tumors of Liver - TBA

13:10-13:20

  • Pathology of Pancreatic Carcinomas - TBA

13:20-13:30

  • Pathology of GEPNET - TBA

13:30-13:40

  • Pathology of GIST - TBA
13:40 - 13:55Break
13:55 – 15:45

Immunotherapy in Gastrointestinal Cancers Course
Moderator: TBA

13:55-14:05

  • Introduction: TBA

14:05-14:15

  • Immunological Basis of Carcinogenesis in Gastrointestinal Tumors: TBA

14:15-14:25

  • Markers for Immunotherapy: TBA

14:25-14:35

  • PD-1 Inhibitors: TBA

14:35-14:45

  • PD-L1 Inhibitors: TBA

14:45-14:55

  • CTLA4 Inhibitors: TBA

14:55-15:05

  • CAR-T Cell Therapies: TBA

15:05-15:15

  • Cancer Vaccines: TBA

15:15-15:25

  • Combination of Radiotherapy with Immunotherapy: TBA

15:25-15:35

  • Adverse Events: TBA

15:35-15:45

  • Current Clinical Practice and Future Directions: TBA
15:45 - 16:00Break
16:00 – 16:50

Endoscopical Interventions and Imaging Course Role of Endoscopy in Gastrointestinal Oncology
Moderator: TBA

16:00-16:10

  • Endoscopic Screening for Colorectal Cancer - TBA

16:10-16:20

  • Role of EUS in Gastrointestinal Lesions - TBA

16:20-16:30

  • Stenting for Esophageal, Gastroduodenal and Colorectal Cancers - TBA

16:30-16:40

  • ERCP and EUS for Hepatopancreaticobiliary Cancers - TBA

16:40-16:50

  • Imaging Small Bowel: Capsule Endoscopy and Enteroscopy - TBA
16:50 - 17:05Break
17:05 - 17:55

Screening in GI Oncology Course
Moderator:
TBA

17:05-17:15

  • CRC Cancer Screening Programs in Turkey and the World - TBA

17:15-17:25

  • Endoscopy, Radiology and Fecal Tests for CRC Screening - TBA

17:25-17:35

  • Molecular Tests in Genetic/Familial Tumors - TBA

17:35-17:45

  • Diagnosis and Treatment of Barret Esophagus - TBA

17:45-17:55

  • Conclusion - TBA
17:55 - 18:10Break
18:10 - 20:00

Fellows Reporting from the Clinics
Moderators: TBA, TBA, TBA, TBA

18:10-18:20

  • Hipomagnesemia - TBA

18:20-18:30

  • BRCA Mutant Pancreatic Cancer - TBA

18:30-18:40

  • Oxaliplatin Induced Thrombocytopenia - TBA

18:40-18:50

  • Sinusoidal Obtruction Syndrome - TBA

18:50-19:00

  • Drug Interactions in Gastrointestinal Oncology - TBA

19:00-19:10

  • Role of Anticoagulant Treatment in Advanced Pancreatic Cancer - TBA

19:10-19:20

  • Practical Issues in G-CSF Treatment in Patients with Gastrointestinal Cancers - TBA

19:20-19:30

  • Treatment Induced Pulmonary Toxicity in GI Cancers - TBA

19:30-19:40

  • Systemic Management of Bone Metastasis in GI Cancers - TBA

19:40-19:50

  • Bone Marrow Involvement and Gastrointestinal Cancers - TBA

19:50-20:00

  • Integrating Quality of Life Measures into the Daily Clinical Practice in GI Oncology - TBA

3 December 2021, Friday

08:30 – 09:50

Session I: Opening Session Impact of Precision Medicine in Colon Cancer
Chairs
: TBA, TBA, TBA

08:30-08:50

  • Clinical Significance of the CMS Classification - TBA

08:50-09:10

  • Role of Immunoscore in Colon and Rectal Cancer - TBA

09:10-09:30

  • Role of ctDNA in MRD Detection, Relapse Monitoring and Treatment Response Monitoring in Colon Cancer - TBA

09:30-09:50

  • Marker Driven Treatment for Metastatic Colon Cancer - TBA
09:50 - 10:45

Session II: Esophageal Cancer Management: How Should I Treat in 2021
Chairs:
TBA, TBA, TBA

09:50-10:10

  • Esophageal Cancer Management: How Should I Treat in 2021 - TBA

10:10-10:25

  • Emerging Systemic Treatment Options for Esophageal Cancer - TBA

10:25-10:40

  • Perioperative Chemotherapy or Neoadjuvant Chemadiotherapy for Esophageal Cancers - TBA

10:40-10:45 Discussion: TBA, TBA, TBA

10:45 - 11:00Coffee Break
11:00 - 11:45Satellite Symposium 1
11:45 - 13:00

Session III: Gastric Cancer: Towards More Individualized Approach
Chairs: TBA, TBA, TBA

11:45-12:05

  • Adjuvant/Neoadjuvant Therapy in Gastric Cancer - TBA

12:05-12:25

  • Role of Radiotherapy as Adjuvant and Neoadjuvant Treatment - TBA

12:25-12:45

  • Advances in the Systemic Treatment of Advanced Gastric Cancer - TBA

12:45-13:00

  • Management of HER-2 Positive Gastric Cancer - TBA
13:00 - 13:45Lunch
13:45 - 14:35

Session IV: Pancreatic Cancer
Chairs: TBA, TBA, TBA

13:45-14:05

  • Adjuvant/Neoadjuvant Treatment in Resectable Pancreas Cancer? - TBA

14:05- 14:20

  • Increasing Role of Genetics and Molecular Alterations in the Management of Pancreatic Cancer - TBA

14:20-14:35

  • Advances in the Systemic Treatment of Pancreatic Cancer - TBA
14:35 - 15:15

Session V: Hepatocellular Tumors
Chairs: TBA, TBA, TBA

14:35-14:50

  • New Perspectives in Classification of HCC - TBA

14:50-15:10

  • Advances in the Systemic Treatment of Hepatocellular Cancer - TBA

15:10-15:15 Discussion: TBA, TBA, TBA

15:15 - 16:00Satellite Symposium 2
16:00 - 16:20Coffee Break
16:20 - 16:55

Session VI: Biliary Tract Cancer
Chairs:
TBA, TBA, TBA

16:20-16:35

  • Molecular Pathways in Biliary Tract Cancers  What Have we Learnt so Far - TBA

16:35-16:55

  • Systemic Treatment for Biliary  Tract Cancer - TBA
16:55 - 17:40

Session VII: Update On GIST Tumors
Chairs: TBA, TBA

16:55-17:15

  • Understanding the Molecular Biology of GISTs - TBA

17:15-17:35

  • Update on GIST management - TBA

17:35-17:40 Discussion: TBA, TBA

17:40 - 18:05

Session VIII: Management of NETs
Chairs:
TBA, TBA

17:40-18:00

  • Systemic Treatment in Advanced GEPNETS - TBA

18:00-18:05 Discussion: TBA, TBA

18:15 - 19:00Meet the Expert Meeting

 

4 December 2021, Saturday

08:30 – 09:10

Session IX: Anal Cancer
Chairs:
TBA, TBA

08:30-08:50

  • Advances is the Multimodality Treatment for Localized Disease - TBA

08:50-09:05

  • New Systemic Treatment Options for Metastatic Disease - TBA

09:05-09:10 Discussion: TBA, TBA

09:10 - 10:10

Session X: Localized Rectal Cancer
Chairs:
TBA, TBA, TBA

09:10-09:30

  • Individualizing Adjuvant/ Neoadjuvant Treatment for Rectal Cancer - TBA

09:30-09:50

  • Surgical Management of Rectal Cancer: Current Approach Future Directions - TBA

09:50-10:10

  • Total Neoadjuvant Treatment and Non Operative Management: Time for Paradigm Shift? - TBA
10:10 - 10:30Coffee Break
10:30 - 11:10

Session XI: Update on Colon Cancer Summary of the Year
Chairs:
TBA, TBA, TBA

10:30-10:50

  • Update on Adjuvant Therapy in Colon Cancer - TBA

10:50-11:10

  • Update on the First-Line Treatment in mCRC - TBA
11:10 - 11:55Satellite Symposium 3
11:55 - 12:55

Session XII: Implications of Age and Gender in the Management of Colon Cancer
Chairs:
TBA, TBA, TBA

11:55-12:15

  • Elderly Patients with Colon Cancers - TBA

12:15-12:35

  • Young Patients with Colon Cancers - TBA

12:35-12:55

  • Gender Differences in Colon Cancers - TBA
12:55 - 13:40Lunch
13:40 - 14:15

Session XIII: A Closer Look on Individualized Treatment in Advanced Colon Cancer
Chairs:
TBA, TBA, TBA

13:40-13:55

  • NTRK Rearrangements in Metastatic Colorectal Cancer - TBA

13:55-14:15

  • Clinical Implications of HER-2 Positivity in Metastatic Colon Cancer - TBA
14:15 - 14:50

Session XIV: New Tissue Agnostics Pathways to Target in GI Cancers
Chairs:
TBA, TBA

14:15-14:30

  • FGFR alterations in GI Cancers - TBA

14:30-14:45

  • Systemic Treatment of GI Cancers with RET Alterations - TBA

14:45-14:50 Discussion: TBA, TBA

14:50 - 15:35Satellite Symposium 4
15:35 - 15:55Coffee Break
15:55 - 16:55

Session XV: Optimizing CRC Treatment in Advanced Stage
Chairs:
TBA, TBA, TBA

15:55-16:15

  • Immunoterapies in mCRC: Where do we Stand Today - TBA

16:15-16:35

  • Role of Maintenance Therapy in Advanced CRC - TBA

16:35-16:50

  • Treatment Beyond Second Line: Choosing Patients - TBA

16:50-16:55 Discussion: TBA, TBA

16:55 – 17:40

Session XVI: Advanced RAS Mutant Colorectal Cancer
Chairs: TBA, TBA

16:55-17:15

  • Clinical Characteristics of RAS Mutant Colorectal Cancers - TBA

17:15-17:35

  • Optimal Systemic Treatment Strategies for Ras Mutant Colorectal Cancer - TBA

17:35-17:40 Discussion: TBA, TBA

17:40 – 18:35

Session XVII: Cytoreductive Surgery and HIPEC
Chairs:
 TBA, TBA

17:40-17:55

  • Cytotoxic Regimens used During Hypertherima - TBA

17:55-18:15

  • Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastrointestinal Cancers - TBA

18:15-18:30

  • Why are Studies Failing with HIPEC - TBA

18:30-18:35 Discussion: TBA, TBA

 

5 December 2021, Sunday

08:30 – 09:30

Session XVIII: We Can Better Understand and Treat Metastatic Colorectal Cancer
Chairs: TBA, TBA, TBA

08:30 - 08:50    

  • Right Versus Left Colon - TBA

08:50 – 09:10   

  • Addressing BRAF Mutant mCRC - TBA

09:10 - 09:30   

  • Controversies on First Line Chemotherapy Regimens - TBA
09:30 – 10:00

Session XIX: Debate
Chairs: TBA, TBA

09:30 - 09:45

  • Irinotecan Based Chemo for First Line is Better - TBA

09:45 - 10:00

  • Oxaliplatin Based Chemo for First Line is Better - TBA
10:00 - 11:15

Session XX: Changing Paradigm in Colorectal Cancer
Chairs: TBA, TBA, TBA

10:00 - 10:15

  • Are we There: Neoadjuvant Treatment for Colon Cancer - TBA

10:15 - 10:35

  • Understanding the Importance of Tumor Microenvironment in CRC - TBA

10:35 - 10:55

  • Genomic/Signature Tools for Prediction of Risk in Early Stage Colon Cancer - TBA

10:55 - 11:10

  • Systemic Therapy for MSI High Colon Cancer - TBA

11:10-11:15 Discussion: TBA, TBA

11:15 - 11:35Coffee Break
11:35 – 12:30

Session XXI: New Options and Newer Approaches
Chairs: TBA, TBA

11:35 - 11:55

  • New Treatment Option for Gastrointestinal Cancers: Trifluridine/Tipiracil Prolongs Survival in Advanced Gastric and Colon Cancer - TBA

11:55 - 12:15

  • Pharmacogenetics for Colon Cancer - TBA

12:15 - 12:30

  • Increasing Role of IMRT in GI Cancers - TBA
12:30 – 13:00Session XXII: Increasing Role of Biosimilars in Gastrointestinal Cancers
Chairs: TBA, TBA
Speaker:TBA
13:00 - 13:10Closing Remarks
Suayib Yalcin